Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

SAN DIEGO, Nov. 7, 2011 /PRNewswire/ -- CareFusion today reported results for the quarter ended Sept. 30, 2011.

"Our revenue and adjusted earnings per share growth for the quarter was driven by increased sales in our Dispensing Technologies and Infusion Systems businesses and the benefit from a lower tax rate," said Kieran Gallahue, chairman and CEO. "During the quarter, we transitioned from our stand-up phase to our foundation building stage, and made progress in our efforts to simplify how we do business and invest in areas to help expand margins and accelerate our top line growth.

Today, we are reaffirming our full-year adjusted diluted earnings per share guidance for fiscal 2012 of $1.80 to $1.90 and revenue growth of 3 to 5 percent over fiscal 2011 on a constant currency basis."

CareFusion's reported results compare to the quarter ended Sept. 30, 2010.

First Quarter ResultsRevenue for the first quarter of fiscal 2012 increased 4 percent to $844 million on a reported basis and 3 percent on a constant currency basis, driven primarily by increased sales in the Dispensing Technologies and Infusion Systems businesses. Operating income was $108 million and income from continuing operations was $67 million, or $0.30 per diluted share. Excluding nonrecurring items, adjusted operating income increased $1 million to $119 million and adjusted income from continuing operations increased $12 million to $76 million, or $0.33 per diluted share. The adjusted tax rate for the quarter was 19.8 percent, primarily driven by a discrete onetime $5 million United Kingdom tax refund related to pre-spinoff periods from Cardinal Health.

CareFusion's financial results were negatively impacted during the quarter by an increase in recall reserves in the company's Medical Systems segment. The company recorded a $12 million charge, or approximately $0.04 per share, the majority of which is related to expenses incurred and future expected costs associated with voluntary field corrections for a portion of its installed base of AVEA® ventilators. While the company is in the process of remediating the affected ventilators, it continues to manufacture and sell its AVEA ventilator products.

Operating expenses, including selling, general and administrative (SG&A), research and development (R&D) and restructuring and acquisition integration charges totaled $319 million, or 38 percent of total revenue. Excluding $11 million of nonrecurring items, adjusted operating expenses totaled $308 million, or 36 percent of total revenue. Adjusted SG&A expenses were $269 million and R&D investments totaled $39 million.

New Reporting SegmentsIn July 2011, the company realigned its businesses under two new global operating segments named Medical Systems and Procedural Solutions. Beginning with the first quarter of fiscal 2012, the company also made a determination to realign its reportable segments with the new operating segments. Accordingly, the company is reporting results under these two segments, which are replacing the Critical Care Technologies and Medical Technologies and Services segments under which the company had previously reported. The Medical Systems segment includes the company's Dispensing Technologies, Infusion Systems and Respiratory Technologies business lines. The Procedural Solutions segment includes the company's Infection Prevention, Medical Specialties and Specialty Disposables business lines. The company has separately provided summary historical financial data for the new reportable segments in a report on Form 8-K filed with the Securities and Exchange Commission on Nov. 2, 2011.

Medical SystemsRevenue for the Medical Systems segment increased 9 percent on a reported basis to $509 million, or 7 percent on a constant currency basis, driven by Dispensing Technologies and Infusion Systems sales. Sales in the company's Dispensing Technologies business increased organically and due to the August 2011 acquisition of Rowa, a Germany-based company specializing in robotic medication storage and retrieval systems for retail and hospital pharmacies. Sales of Infusion Systems increased as a result of core business growth primarily in the dedicated disposable product volumes. These increases were partially offset by a decrease in Respiratory Technologies sales, primarily due to lower sales of ventilators in Western Europe. Segment profit increased 29 percent to $88 million, and adjusted segment profit increased 6 percent to $95 million, both of which were negatively impacted by the $12 million increase in the company's recall reserves.

Procedural SolutionsRevenue for the Procedural Solutions segment decreased 2 percent on a reported basis to $335 million, or 4 percent on a constant currency basis, driven by the loss of sales from divesting the company's OnSite Services business in March 2011. This decrease was partially offset by an increase in sales in the company's Infection Prevention business. Net of the OnSite Services business divestiture, segment revenues grew 1 percent in the first quarter compared to the prior year period. Segment profit increased 82 percent to $20 million due to margin expansion and strong expense controls, and adjusted segment profit decreased 14 percent to $24 million, primarily driven by the divestiture of the OnSite Services business.

Fiscal 2012 Outlook CareFusion is reiterating financial guidance for the fiscal year ending June 30, 2012. The company continues to expect fiscal 2012 revenues to grow 3 to 5 percent on a constant currency basis compared to fiscal 2011 revenue of $3.53 billion and for adjusted diluted earnings per share to be in the range of $1.80 to $1.90. The guidance is based on an assumed diluted weighted average outstanding share count of approximately 226 million.

Conference CallCareFusion will host a conference call today at 2 p.m. PST (5 p.m. EST) to discuss earnings results for the first quarter ended Sept. 30, 2011.

To access the call and corresponding slide presentation, visit the Investors page at www.carefusion.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

Investors and other interested parties may also access the call by dialing (800) 901-5213 within the U.S. or (617) 786-2962 from outside the U.S., and use the access code 61573117. A replay of the conference call will be available from 5 p.m. PST (8 p.m. EST) on Nov. 7 through 8:59 p.m. PST (11:59 p.m. EST) on Nov. 14 and can be accessed by dialing (888) 286-8010 in the U.S. or (617) 801-6888 Internationally and using the access code 14995413.

About CareFusion
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® skin prep products, MedMined™ services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

Use of Non-GAAP Financial Measures by CareFusion Corporation This CareFusion news release presents non-GAAP financial measures that exclude certain amounts, as follows:  "adjusted operating expenses", "adjusted SG&A expenses" and "adjusted operating income", which exclude nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges; "adjusted income from continuing operations", "adjusted diluted earnings per share from continuing operations" and "adjusted tax rate", which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges and nonrecurring tax items; and "adjusted segment profit", which excludes nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.

The most directly comparable measure for these non-GAAP financial measures are operating expenses, SG&A expenses, operating income, income from continuing operations, diluted earnings per share from continuing operations, tax rate, and segment profit (the most comparable GAAP measures). The company has included below unaudited adjusted financial information for the quarters ended Sept. 30, 2011 and 2010, which includes a reconciliation of GAAP to non-GAAP financial measures.

In addition, CareFusion presents the non-GAAP financial measure "adjusted diluted earnings per share" on a forward-looking basis. The most directly comparable forward-looking GAAP measure for the company is diluted earnings per share. CareFusion is unable to provide a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable forward-looking GAAP measure, because the company cannot reliably forecast restructuring and acquisition integration costs, and other nonrecurring costs. Please note that the unavailable reconciling items could significantly impact CareFusion's future financial results. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding CareFusion's financial condition and results of operations is included as Exhibit 99.3 to CareFusion's report on Form 8-K filed with the Securities and Exchange Commission on Nov. 7, 2011.

Cautions Concerning Forward-looking StatementsThe CareFusion news release and the information contained herein contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of Nov. 7, 2011. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CAREFUSION CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)Quarter Ended September 30,(in millions, except per share amounts)20112010Revenue

$

844

$

811Cost of Products Sold417398Gross Margin427413Selling, General and Administrative Expenses273272Research and Development Expenses3940Restructuring and Acquisition Integration Charges722Operating Income10879Interest Expense and Other, Net 2523Income Before Income Tax8356Provision for Income Tax1620Income from Continuing Operations6736Income from Discontinued Operations, Net of Tax-2Net Income

$

67

$

38Per Share Amounts:(1)Basic Earnings per Common Share:Continuing Operations

$

0.30

$

0.17Discontinued Operations

$

-

$

0.01Basic Earnings per Common Share

$

0.30

$

0.17Diluted Earnings per Common Share:Continuing Operations

$

0.30

$

0.17Discontinued Operations

$

-

$

0.01Diluted Earnings per Common Share

$

0.30

$

0.17Weighted-Average Number of Common Shares Outstanding:Basic223.8222.1Diluted226.3223.9____________1Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from the table may not equal the per share amounts presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended September 30, 2011Nonrecurring(in millions, except per share amounts)GAAP Items(1)Adjusted(2)Revenue(3)$

844

$

-

$

844Cost of Products Sold417-417Gross Margin427-427Selling, General and Administrative Expenses273(4)269Research and Development Expenses39-39Restructuring and Acquisition Integration Charges 7(7)-Operating Income10811119Interest Expense and Other, Net 25-25Income Before Income Tax831194Provision for Income Tax16218Net Income $

67

$

9

$

76Per Share Amounts:(4)Basic Earnings per Common Share$

0.30

$

0.04

$

0.34Diluted Earnings per Common Share$

0.30

$

0.04

$

0.33Weighted-Average Number of Common Shares Outstanding:Basic223.8223.8223.8Diluted 226.3226.3226.3Effective Tax Rate19.0%25.5%19.8%____________1Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring charges.  2Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.3Revenues increased $33 million or 4% for the quarter ended September 30, 2011 compared to 2010, on a constant currency basis, the increase is 3%.4Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended September 30, 2010DiscontinuedNonrecurring(in millions, except per share amounts)GAAP Operations(1)Items(2)Adjusted(3)Revenue$

811

$

-

$

-

$

811Cost of Products Sold398--398Gross Margin413--413Selling, General and Administrative Expenses272-(17)255Research and Development Expenses40--40Restructuring and Acquisition Integration Charges 22-(22)-Operating Income79-39118Interest Expense and Other, Net 23--23Income Before Income Tax56-3995Provision for Income Taxes20-1131Income from Continuing Operations36-2864Income from Discontinued Operations, Net of Tax2(2)---Net Income

$

38

$

(2)

$

28

$

64.Per Share Amounts:(4)Basic Earnings per Common Share

$

0.17

$

(0.01)

$

0.13

$

0.29Diluted Earnings per Common Share

$

0.17

$

(0.01)

$

0.13

$

0.29Weighted-Average Number of Common Shares Outstanding:Basic222.1222.1222.1222.1Diluted223.9223.9223.9223.9Effective Tax Rate34.4%n/a27.8%31.7%____________1Reflects the impact of the divestiture of the International Surgical Products (ISP) business.  The ISP business was divested in April 2011, and has been classified as discontinued operations. 2Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items.  3Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.4Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED SEGMENT FINANCIAL INFORMATION(UNAUDITED)Quarter Ended September 30, 2011Nonrecurring(in millions)GAAP Items(1)Adjusted(3)Medical SystemsRevenue$

509

$

-

$

509Operating Income $

88

$

7

$

95Procedural SolutionsRevenue$

335

$

-

$

335Operating Income $

20

$

4

$

24Quarter Ended September 30, 2010Nonrecurring(in millions)GAAP(4)Items(2)Adjusted(3)Medical SystemsRevenue$

468

$

-

$

468Operating Income $

68

$

22

$

90Procedural SolutionsRevenue$

343

$

-

$

343Operating Income $

11

$

17

$

28____________1Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring charges.  2Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.  Certain nonrecurring costs previously reported were applicable to the International Surgical Products (ISP) business and therefore were reclassified to be reflected as part of that business.3Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.4Previously reported GAAP amounts have been adjusted to reflect the impact of the divestiture of the ISP business, and re-segmentation of the Company's businesses into two new reportable segments.  The ISP business was divested in April 2011, and has been classified as discontinued operations. CAREFUSION CORPORATIONSEGMENT AND SELECT BUSINESS LINE REVENUES(UNAUDITED)Quarter Ended September 30,(in millions) 20112010(1)Percent
ChangeMedical SystemsDispensing Technologies

$

237

$

205

16

%Infusion Systems206192

7Respiratory Technologies6065

(8)Other66

-Total Medical Systems

$

509

$

468

9Procedural SolutionsInfection Prevention

$

138

$

135

2

%Medical Specialties7878

-Specialty Disposables6670

(6)Other5360

(12)Total Procedural Solutions

$

335

$

343

(2)Total CareFusion$

844

$

811

4

%____________1Previously reported GAAP amounts have been adjusted to reflect the impact of the divestiture of the International Surgical Products (ISP) business, and re-segmentation of the Company's businesses into two new reportable segments. The ISP business was divested in April 2011, and has been classified as discontinued operations. (Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)


'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):